Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Trial StartSIL204Positive

AI Analysis

Summary

Silexion Therapeutics has successfully initiated a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center.

Clinical Trial Data

Phase

2/3

Importance:5/10

Sentiment:

0.60

pancreatic_cancerphase_2_3_trialtrial_initiationSIL204

Related Companies

$SLXN

Read the original article

Published by yahoo_finance on July 29, 2026 11:00 AM

Read Original